



FINAL

ENDOMETRIAL CANCER COMMITTEE
THURSDAY, OCTOBER 18, 2018, 9:30AM – 10:30AM
AMPHITHEATRE, KLINIKUM DER UNIVERSITÄT MÜNCHEN, DEPARTMENT OF GYNECOLOGY AND OBSTETRICS,
CAMPUS INNENSTADT, MAISTR. 11, MÜNCHEN
CHAIR: S.GREGGI CO-CHAIR: C.CREUTZBERG
HARMONIZATION LIAISONS: VERHOEVEN (OPS); TU/EMBLETON (STATS)
PLEASE SIGN ATTENDANCE FORMS

AGENDA

Welcome and Introductions Greggi

COI Disclosures (real or perceived)

Approval of report/minutes: May 2018 (posted on GCI website)

Motion: _____ Seconded: _____

CLOSED/PUBLISHED STUDIES Greggi

ONGOING TRIALS:

MITO (ECCO)	Greggi
NCRI (Statec)	McNeish
AGO (Eclat)	Harter
NSGO (EN2)	Mirza
DGOG (Portec-4a)	Creutzberg
COGI (SAVE)	Gaffney
MITO (AEC)	Greggi
NSGO (EN1-Fandango; EN3-Paleo)	Mirza
BGOG (SIENDO)	Vergote
MANGO (AtTEND)	Colombo
NRG-GOG	Powell

CHALLENGING DEBATE:

- Lymphovascular space invasion (LVSI+ve) in patients not submitted to lymphadenectomy (NX): retroperitoneal surgical restaging (no further treatment if N0), or adjuvant ERT?
- Any role of CA125 in EC workup and treatment?

Dave Gaffney; Andrea Lissoni

ADJOURN